Huang Po-Han, Yu Jen, Chu Yin-Yi, Lin Yang-Hsiang, Yeh Chau-Ting
Department of Gastroenterology and Hepatology, New Taipei Municipal TuCheng Hospital, New Taipei 236, Taiwan.
College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
J Clin Med. 2022 May 2;11(9):2550. doi: 10.3390/jcm11092550.
Patients with advanced hepatocellular carcinoma (HCC) are treated by immunotherapy and/or targeted agents, such as sorafenib. Several single nucleotide polymorphisms (SNPs) and clinical scores have been proposed as prognostic markers in HCC patients treated with sorafenib. This study aimed to validate the prognostic values of these markers in a tertiary referral medical center. Two independent cohorts (cohort-1 [n = 97] and cohort-2 [n = 60]) of advanced HCC patients treated with sorafenib monotherapy were enrolled. Univariate followed by multivariate Cox proportional hazard analysis identified Child−Pugh (CP) score (p < 0.001) and renal insufficiency during treatment (p < 0.001) as independent predictors in cohort-1 patients. The same analytic method revealed ascites (p = 0.000), CP score (p = 0.001), infection during treatment (p < 0.001), and ATP-binding cassette subfamily G member 2 (ABCG2)-rs2231142 genotype (p = 0.003) as independent predictors in cohort-2 patients. ABCG2-rs2231142 genotype “CC” was associated with unfavorable overall survival in sorafenib-treated HCC patients. In conclusion, the CP score and ABCG2-rs2231142 genotype served as independent survival predictors for advanced HCC patients receiving sorafenib treatment.
晚期肝细胞癌（HCC）患者采用免疫疗法和/或靶向药物（如索拉非尼）进行治疗。已经提出了几种单核苷酸多态性（SNP）和临床评分作为接受索拉非尼治疗的HCC患者的预后标志物。本研究旨在在一家三级转诊医疗中心验证这些标志物的预后价值。纳入了两个接受索拉非尼单药治疗的晚期HCC患者独立队列（队列1 [n = 97]和队列2 [n = 60]）。单因素分析后进行多因素Cox比例风险分析，结果显示在队列1患者中，Child-Pugh（CP）评分（p < 0.001）和治疗期间肾功能不全（p < 0.001）是独立预测因素。相同的分析方法显示，在队列2患者中，腹水（p = 0.000）、CP评分（p = 0.001）、治疗期间感染（p < 0.001）和ATP结合盒转运体G亚家族成员2（ABCG2）-rs2231142基因型（p = 0.003）是独立预测因素。ABCG2-rs2231142基因型“CC”与接受索拉非尼治疗的HCC患者不良总生存期相关。总之，CP评分和ABCG2-rs2231142基因型是接受索拉非尼治疗的晚期HCC患者的独立生存预测因素。
